BioNTech US
在场
BioNTech 是一家在股票代码 BNTX (DE) 下上市的公司。
BioNTech 在 3 个国家有直接业务。BioNTech 拥有 3家子公司，其中包括 BioNTech IMFS、BioNTech US 和 InstaDeep。
他们在：
涉及BioNTech的并购和融资。
- BioNTech 刚刚宣布为 145 筹款数百万美元。 (公布2024六月5号).
- BioNTech 已收购 InstaDeep (公布2023八月1号).
- BioNTech has announced the acquisition of InstaDeep (公布2023一月12号).
高管
查看带有其 6 名主要高管的组织结构图
BioNTech US 搜索最多的简介
- Richard Gaynor, President of and Chief of R&D
- Zach Taylor, Vice President of Corporate Development and Strategy
- Kelledy Manson, Vice President of Product Development
高管在BioNTech变化
- Annemarie HanekampAnnemarie Hanekamp 将于20246月30作为 Chief Commercial Officer 加入公司 (新闻发布的2024三月21号).
- Sean Marett, Chief Business Officer and Chief Commercial Officer, 将于 20243月30 退休 (新闻发布的2024三月11号).
- James Ryan 曾任 Chief Legal Officer, 将于 20243月30 升职为 Chief Legal Officer and Chief Business Officer (新闻发布的2024三月11号).
创建提醒
跟踪 BioNTech US 的高管变动
生物技术
BioNTech 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
BioNTech US 的最新新闻稿
- BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2 | BioNTech
- BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2 | BioNTech
- BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021 | BioNTech
- BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162 | BioNTech
- Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial | BioNTech
- Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 | BioNTech
- Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19 | BioNTech
- Biopharma Leaders Unite to Stand with Science | BioNTech
- BioNTech and Pfizer Receive Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial for COVID-19 Vaccine Candidate BNT162b2 | BioNTech
- BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR | BioNTech
- View more press releases Close
关于 BioNTech US 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Richard Gaynor 
